Abiraterone Acetate

The addition of ipatasertib to abiraterone enhanced antitumor activity and improved radiographic PFS as first-line therapy for metastatic castration-resistant prostate cancer, according to data presented at ESMO Virtual Congress 2020.

Talazoparib monotherapy induced promising antitumor activity in men with metastatic castration-resistant prostate cancer who previously received docetaxel, according to the first interim analysis of the single-arm, phase 2 TALAPRO-1 study presented at Genitourinary Cancers Symposium.

BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with previously treated metastatic castration-resistant prostate cancer, according to results of the randomized CARD study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — Olaparib significantly improved radiographic PFS compared with horomone therapy for men with metastatic castration-resistant prostate cancer who had homologous recombination repair gene alterations and received prior treatment with new hormonal agents, according to results of the randomized phase 3 PROfound study presented at European Society for Medical Oncology Congress.

Abiraterone acetate and enzalutamide appeared to increase the risk for death among older men with advanced prostate cancer and pre-existing cardiovascular conditions, according to results of a population-based retrospective study published in European Urology.

Olaparib significantly extended radiographic PFS compared with standard-of-care treatment among a specific subset of men with advanced prostate cancer, according to the agent’s manufacturers.